Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · VENMAX DRUGS AND PHARMACEUTICA · 6 November 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
VENMAX DRUGS AND PHARMACEUTICA
BSE: 531015
BSE: 531015
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
VENMAX DRUGS AND PHARMACEUTICA
StateQ1 FY27 filed
Last close · 6 Nov 2026₹13.90
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA33.9 · 1.14 · 99.0
VENMAX DRUGS AND PHARMACEUTICA is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1 | 8 |
| EBITDA (ex other income) | (0) | (0) | (0) | (1) | 0 |
| margin % | — | — | — | (131.3) | 1.5 |
| Owners' profit | 2 | 0 | 0 | (0) | 0 |
| EPS, as reported (₹) | 3.52 | 0.43 | 0.12 | (0.02) | 0.21 |
| ROE % · ROCE % | (196.4) · (197.4) | (31.6) · (31.8) | (9.9) · (13.5) | (0.2) · (0.3) | 1.8 · 2.0 |
| Debt / equity (x) | (0.37) | (0.49) | (0.54) | 0.01 | 0.02 |
| Cash from operations | 2 | (0) | 0 | (2) | (11) |
| Capex | 0 | 0 | 0 | 0 | 0 |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · VENMAX DRUGS AND PHARMACEUTICA · 6 November 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1 | 1 | 2 | 4 | 2 |
| Profit before tax | (0) | (0) | 1 | 0 | 0 | 0 | 0 | 0 |
| Net profit | (0) | (0) | 1 | 0 | 0 | 0 | 0 | 0 |
| EPS (₹) | (0.58) | (0.95) | 1.49 | 0.07 | 0.05 | 0.05 | 0.21 | 0.10 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,46,270 | 40.7 | 4.98 | 24.9 | 5.5 | 8.0 | 11.8 | 29.3 |
| DIVI S LABORATORIES LTD | 2,73,493 | 93.6 | 16.32 | 79.4 | 15.3 | 18.8 | 8.7 | 40.7 |
| TORRENT PHARMACEUTICALS L | 1,80,500 | 80.2 | 9.82 | 42.6 | 6.0 | 4.0 | 11.8 | 33.5 |
| LAURUS LABS LIMITED | 1,26,430 | 94.3 | 20.45 | 72.4 | 12.9 | 14.2 | 7.2 | 34.0 |
| ZYDUS LIFESCIENCES LTD | 1,19,550 | 28.8 | 3.94 | 15.4 | 6.4 | 6.8 | 12.4 | 24.0 |
| DR. REDDY S LABORATORIES | 1,14,646 | 40.9 | 2.93 | 18.5 | 3.4 | 4.2 | 12.1 | 19.9 |
| CIPLA LTD | 1,13,988 | 39.3 | 3.21 | 19.3 | 4.6 | 6.2 | 8.0 | 18.7 |
| MANKIND PHARMA LIMITED | 1,04,902 | 46.8 | 5.88 | 30.6 | 7.2 | 7.3 | — | 27.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 33.9 | 29.3 | 92 of 160 | 43% |
| P/B | 1.1 | 3.1 | 29 of 163 | 83% |
| ROCE | 2.0 | 8.0 | 138 of 177 | 22% |
| ROE | 1.8 | 6.8 | 131 of 165 | 21% |
| Debt / Equity | 0.0 | 0.1 | 51 of 166 | 70% |
| EBITDA margin | 4.7 | 14.6 | 136 of 178 | 24% |
| Revenue growth | 104.9 | 17.1 | 11 of 163 | 94% |
| Profit growth | 211.8 | 21.8 | 21 of 157 | 87% |
| Market cap | 16 | 814 | 171 of 181 | 6% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · VENMAX DRUGS AND PHARMACEUTICA · 6 November 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 5 Nov 2026 · Board meeting set to approve September quarter results | results | low | — | — |
| 26 Oct 2026 · Shareholders approve Hatri Pharma amalgamation with Venmax | strategic transactions | medium | — | — |
| 24 Oct 2026 · Shareholders meet on Hatri Pharma merger; voting results pending | board shareholder meetings | low | — | — |
| 8 Oct 2026 · Quarterly compliance certificate under SEBI Regulation 74(5) for Sep 2026 | compliance | minimal | — | — |
| 28 Sept 2026 · 37th AGM results: all resolutions approved, key director elevation to MD | board shareholder meetings | low | — | — |
| 26 Sept 2026 · Summary of the proceedings of 37th Annual General Meeting of the shareholders held at 12.30 P.M. through video conferencing mode. | board shareholder meetings | low | — | — |
| 25 Sept 2026 · Trading Window Closure from Oct 1 for Q2 FY27 Results | compliance | minimal | — | — |
| 22 Sept 2026 · NCLT-convened shareholder meeting to approve Hatri Pharma merger | strategic transactions | high | — | — |
| 8 Sept 2026 · NCLT orders shareholder meeting for Venmax Hatri Pharma merger | strategic transactions | medium | — | — |
| 1 Sept 2026 · Venmax Drugs submits FY26 Annual Report; AGM on September 26, 2026 | compliance | minimal | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in